Specifically, in response to ICIs resistance, tumor cells can evade immune surveillance by upregulating PD-L1 expression, modulating the number and function of immunosuppressive cells, or activating alternative immune checkpoint molecules. The gene discussed is CD274; the disease is neoplasm.